Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Payables (2016 - 2025)

Ascendis Pharma A's Payables history spans 7 years, with the latest figure at $539.8 million for Q4 2023.

  • For Q4 2023, Payables rose 369.59% year-over-year to $539.8 million; the TTM value through Dec 2023 reached $539.8 million, up 369.59%, while the annual FY2023 figure was $542.7 million, 357.01% up from the prior year.
  • Payables for Q4 2023 was $539.8 million at Ascendis Pharma A, up from $114.9 million in the prior quarter.
  • Across five years, Payables topped out at $539.8 million in Q4 2023 and bottomed at $8.0 million in Q4 2021.
  • The 4-year median for Payables is $70.5 million (2020), against an average of $172.2 million.
  • The largest annual shift saw Payables crashed 69.35% in 2021 before it surged 1336.42% in 2022.
  • A 4-year view of Payables shows it stood at $26.1 million in 2020, then plummeted by 69.35% to $8.0 million in 2021, then soared by 1336.42% to $114.9 million in 2022, then skyrocketed by 369.59% to $539.8 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Payables are $539.8 million (Q4 2023), $114.9 million (Q4 2022), and $8.0 million (Q4 2021).